Autoimmune Orbital Disease · Surgeon Series
Graves' disease doesn't
stop at the thyroid.
It can push the eye itself.
Thyroid eye disease is not a side-effect of abnormal hormone levels — it is a separate autoimmune attack on the tissue inside the eye socket, in a bony space that has nowhere to expand. Here is why the eye is pushed forward, how doctors score whether it is still active, when it turns into a genuine emergency, and how treatment is sequenced from medicine to surgery.
develop visible TED
inflammatory-phase disease
window before it stabilises
Section 01 — Not Just "Thyroid Eyes"
An autoimmune disease
of the eye socket —
that happens to share a trigger.
"Thyroid eyes" is the phrase patients usually hear, and it undersells what is actually happening. Thyroid eye disease (TED), also called Graves' orbitopathy or Graves' ophthalmopathy, is the immune system attacking the fat, connective tissue and muscles that fill the eye socket — not the eye itself, and not a direct consequence of having too much or too little thyroid hormone circulating.
The connection to the thyroid is real but indirect: in Graves' disease, antibodies form against the TSH receptor, driving the thyroid to overproduce hormone. That same receptor, it turns out, is also expressed on fibroblasts inside the orbit. The antibodies activate those orbital fibroblasts too, triggering swelling, fat expansion and glycosaminoglycan deposition that enlarges the extraocular muscles — inside a bony orbit that, unlike the thyroid gland, cannot simply grow to accommodate the extra volume. That mismatch between tissue expansion and a fixed bony space is the entire mechanical story of TED.
Thyroid eye disease is an autoimmune inflammatory condition of the orbit, most often occurring alongside Graves' hyperthyroidism because the same TSH-receptor antibodies act on both the thyroid gland and orbital tissue. It is not simply "what happens to your eyes when your thyroid is high" — the eye disease can appear before hormone levels are corrected, after, or even in people whose thyroid function is normal. What decides the clinical picture is not the hormone level but how much the orbital tissue swells inside a bony space that has no room to give, and whether that crowding reaches the optic nerve at the back.
Section 02 — Interactive
The same swelling,
two different directions.
When the extraocular muscles enlarge inside the orbit, the extra tissue has to go somewhere. In a more fat-compliant orbit, it tends to push the eye forward — proptosis. In a tighter, more fibrotic orbit, the same swelling crowds backward toward the orbital apex, where the optic nerve exits — the pattern most associated with vision-threatening compression, sometimes with only modest forward bulging to show for it. Adjust muscle enlargement and orbital phenotype below to see why the two patterns need very different levels of concern.
This dual-outcome idea — forward displacement versus posterior crowding — is why two patients with what looks like the same degree of muscle swelling on a scan can have very different risk profiles. A proptotic eye is visually obvious and distressing, but a comparatively "good-looking" eye with tight apical crowding can be the one quietly losing optic nerve function, which is exactly why imaging and a formal work-up matter more than how bulging the eye appears from across a room.
Section 03 — The Two-Phase Course
Active, then stable.
Treatment depends
on which one you're in.
TED does not progress in a straight line. Most patients pass through an active, inflammatory phase — pain, redness, swelling, progressive change on exam — that gradually burns out into a stable, fibrotic phase where the tissue changes are fixed but no longer actively worsening. This pattern is often described by Rundle's curve: a rise in severity over the active phase, a plateau, and then a partial spontaneous improvement before disease activity settles. Anti-inflammatory and immunomodulatory treatments are aimed at the active phase; rehabilitative surgery is deliberately deferred until the disease has been stable for months.
To decide which phase a patient is in, ophthalmologists use the Clinical Activity Score (CAS), a bedside checklist of inflammatory signs — spontaneous orbital pain, pain with eye movement, redness of the eyelids and the white of the eye, swelling of the eyelids and conjunctiva, and swelling of the caruncle. A score of 3 or more out of 7 is generally taken as active disease, and it is this score — not the thyroid hormone level on a blood test — that most directly informs whether steroids or other immunomodulatory therapy are likely to help.
| Feature | Active phase | Stable (fibrotic) phase |
|---|---|---|
| Typical duration | Commonly several months up to roughly two years | Indefinite once reached; tissue changes are largely fixed |
| Exam findings | Pain, redness, progressive swelling, worsening measurements visit to visit | Stable measurements over repeated visits; signs of inflammation resolved |
| CAS | Typically 3 or more out of 7 | Typically below 3 |
| Primary treatment lever | Corticosteroids, other immunomodulatory or IGF-1R-targeted therapy, orbital radiotherapy in selected cases | Rehabilitative surgery: decompression, strabismus, eyelid procedures |
| Smoking status | Cessation strongly advised — smoking worsens both severity and treatment response | Cessation still relevant to long-term stability |
Section 04 — What It Looks Like
From eyelid retraction
to a genuine emergency.
Severity spans a wide range. Many patients have mild, mostly cosmetic and irritative disease; a minority progress to something that threatens vision. Recognising where a given presentation sits on that spectrum is the point of the clinical exam.
| Sign | What it is | Severity signal |
|---|---|---|
| Eyelid retraction | Upper lid sits higher than normal, exposing white sclera above the iris | Common, often the earliest visible sign |
| Lid lag on downgaze | Upper lid fails to follow the eye smoothly when looking down | Common, mild-to-moderate disease |
| Proptosis / exophthalmos | Forward protrusion of the eye, measured by exophthalmometry | Variable severity; degree alone does not predict nerve risk |
| Chemosis & conjunctival injection | Swelling and redness of the eye's surface membrane | Marker of active inflammation (part of CAS) |
| Restrictive strabismus / diplopia | Fibrotic, non-elastic muscles (commonly the inferior and medial recti) restrict eye movement, causing double vision | Functionally disabling; usually addressed once stable |
| Exposure keratopathy | Cornea dries and can ulcerate when lids can no longer fully close over a proptotic eye | Sight-threatening if severe |
| Compressive optic neuropathy | Apex crowding presses on the optic nerve, reducing colour vision and acuity | Ophthalmic emergency |
Section 05 — The Evidence
What treatment trials
actually show.
Management has shifted meaningfully with the arrival of targeted medical therapy for active-phase disease. Teprotumumab, a monoclonal antibody against the IGF-1 receptor — a co-signalling partner of the TSH receptor implicated in driving orbital fibroblast activity — was studied against placebo in randomised trials and represented the first therapy purpose-built for TED rather than adapted from general immunosuppression.
Illustrative visualisation of the direction and rough magnitude reported in the pivotal teprotumumab trial literature — see References. Rounded figures, not exact trial statistics, and not a substitute for the original data.
The pivotal randomised trial of teprotumumab, published by Douglas and colleagues in the New England Journal of Medicine, established the proptosis-responder benefit summarised above and led to regulatory approval for active TED in the United States. It is not free of trade-offs: the trial and subsequent post-approval experience documented side effects including elevated blood glucose, muscle spasms, and hearing-related symptoms such as tinnitus or hearing impairment, some of which have persisted after treatment in a subset of patients — which is why candidacy, baseline hearing and glucose status, and informed counselling on the risk profile matter as much as the efficacy numbers.
The European Group on Graves' Orbitopathy (EUGOGO) consensus guidelines, most recently updated in 2021, remain the reference framework most clinicians outside pivotal-trial settings use to classify severity (mild / moderate-to-severe / sight-threatening) and route patients to the appropriate pathway — observation and risk-factor control for mild disease, immunomodulatory therapy for active moderate-to-severe disease, and urgent intervention for sight-threatening disease.
for active disease
EUGOGO guidelines
in fixed order
Section 06 — Risk, Honestly Stated
Medical therapy
and surgery
both carry real trade-offs.
Neither the medical nor the surgical pathway is risk-free, and a guide that only lists one side is not useful for a patient actually weighing the decision with their care team.
| Approach | What it's for | Real trade-offs |
|---|---|---|
| Corticosteroids (oral/IV) | Active-phase inflammation, moderate-to-severe or sight-threatening disease | Weight gain, mood changes, glucose elevation, bone density loss with prolonged use |
| Teprotumumab | Active, moderate-to-severe disease, particularly with troubling proptosis | Hyperglycaemia, muscle spasm, infusion reactions, hearing impairment/tinnitus that can be lasting |
| Orbital radiotherapy | Active disease, sometimes combined with steroids | Modest effect on its own by most series; not appropriate in diabetic retinopathy or in very young patients |
| Orbital decompression surgery | Stable disease with disfiguring proptosis or urgent optic nerve compression | Can worsen or induce new double vision, numbness, sinus-related complications |
| Strabismus surgery | Stable disease with persistent restrictive diplopia | Outcomes less predictable than routine strabismus surgery due to fibrotic muscle behaviour; may need more than one procedure |
| Eyelid surgery | Stable disease with persistent lid retraction or exposure | Under- or over-correction possible; done last so earlier steps aren't undone |
Section 07 — Where the Decision Gets Made
A team decision,
built on a specific work-up.
TED management sits between endocrinology and ophthalmology, and the useful work-up looks the same regardless of which specialist a patient sees first: thyroid function tests and TSH-receptor antibody titre, a CAS assessment, Hertel exophthalmometry to measure proptosis objectively, formal visual field and colour vision testing if apex crowding is suspected, and orbital CT or MRI when surgery or a compressive-neuropathy question is on the table.
A patient with Graves' disease and only mild-looking forward eye protrusion reports new difficulty distinguishing colours and a subtle dimming in one eye. On the appearance of the eyes alone, this would not seem urgent — there is no dramatic bulging. But imaging shows disproportionate crowding of the muscles at the orbital apex relative to how far the eye has moved forward, consistent with a tight, fibrotic orbital phenotype. The colour vision change is the tell: it prompts urgent visual field testing and same-week ophthalmology referral rather than routine follow-up, because compressive optic neuropathy can be present with only modest visible proptosis.
Once the disease is confirmed stable — a low CAS sustained across repeat visits, not just a single good day — surgical rehabilitation, if needed, follows a fixed order: orbital decompression first (to correct proptosis and relieve any apex crowding), then strabismus surgery (to correct the diplopia decompression itself did not fix and may have shifted), then eyelid surgery last (retraction repair or blepharoplasty, once the eye's final position is settled). Each step is sequenced this way because operating out of order risks undoing the step before it.
Section 08 — FAQ
Frequently asked questions
about thyroid eye disease.
Thyroid eye disease (TED), also called Graves' orbitopathy or Graves' ophthalmopathy, is an autoimmune condition in which the immune system attacks tissue inside the eye socket — the fat, connective tissue and muscles that move the eye — causing inflammation, swelling and, over time, tissue enlargement within a bony space that cannot expand to make room. It is most commonly linked to Graves' disease, the autoimmune cause of an overactive thyroid, but the eye disease and the thyroid hormone level do not always move together.
No. An overactive thyroid (hyperthyroidism) is a hormone problem; thyroid eye disease is a separate autoimmune process that happens to share the same underlying trigger — antibodies against the TSH receptor, which is also present on cells in the orbit. TED can appear before, during, or after thyroid hormone levels are corrected, and a minority of cases occur in people whose thyroid function is normal or even underactive.
The Clinical Activity Score (CAS) is a checklist ophthalmologists use to judge whether TED is currently in its active, inflammatory phase — scoring signs such as spontaneous orbital pain, pain on eye movement, redness and swelling of the lids and surface of the eye. A score of 3 or more out of 7 is generally taken to mean the disease is active, which is the main factor in deciding whether anti-inflammatory or immunomodulatory medical treatment is likely to help, as opposed to waiting for the disease to burn out before considering surgery.
TED becomes sight-threatening — a genuine ophthalmic emergency — in two situations: compressive optic neuropathy, where swollen muscles crowd the orbital apex and press on the optic nerve, and severe corneal exposure, where the eyelids can no longer close over a proptotic eye, risking corneal ulceration. Warning signs include a drop in colour vision or visual acuity, and either needs urgent same-week ophthalmology assessment, not a routine follow-up.
Teprotumumab is a monoclonal antibody that blocks the IGF-1 receptor, a co-signalling partner of the TSH receptor implicated in driving orbital tissue expansion in TED. In its pivotal randomised trial, roughly four out of five patients treated with teprotumumab achieved a clinically meaningful reduction in eye protrusion, compared to roughly one in ten on placebo, and it also improved double vision and disease activity scores for many patients. It is given as an infusion course and carries its own side-effect profile, including elevated blood sugar, muscle cramps, and hearing-related symptoms that require monitoring.
Once the disease has been stable and inactive for some months, surgical rehabilitation is generally sequenced as orbital decompression first, then eye-muscle (strabismus) surgery, then eyelid surgery — because each step can change the eye's position and the tension on nearby tissue, which would undo work done out of order. Decompression is done first because moving the eye further back or removing crowding tissue is most likely to require the muscle and eyelid positions to be readjusted afterward, not the reverse.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Autoimmune Orbital Disease · Surgeon Series
Graves' disease doesn't
stop at the thyroid.
It can push the eye itself.
Thyroid eye disease is not a side-effect of abnormal hormone levels — it is a separate autoimmune attack on the tissue inside the eye socket, in a bony space that has nowhere to expand. Here is why the eye is pushed forward, how doctors score whether it is still active, when it turns into a genuine emergency, and how treatment is sequenced from medicine to surgery.
develop visible TED
inflammatory-phase disease
window before it stabilises
Section 01 — Not Just "Thyroid Eyes"
An autoimmune disease
of the eye socket —
that happens to share a trigger.
"Thyroid eyes" is the phrase patients usually hear, and it undersells what is actually happening. Thyroid eye disease (TED), also called Graves' orbitopathy or Graves' ophthalmopathy, is the immune system attacking the fat, connective tissue and muscles that fill the eye socket — not the eye itself, and not a direct consequence of having too much or too little thyroid hormone circulating.
The connection to the thyroid is real but indirect: in Graves' disease, antibodies form against the TSH receptor, driving the thyroid to overproduce hormone. That same receptor, it turns out, is also expressed on fibroblasts inside the orbit. The antibodies activate those orbital fibroblasts too, triggering swelling, fat expansion and glycosaminoglycan deposition that enlarges the extraocular muscles — inside a bony orbit that, unlike the thyroid gland, cannot simply grow to accommodate the extra volume. That mismatch between tissue expansion and a fixed bony space is the entire mechanical story of TED.
Thyroid eye disease is an autoimmune inflammatory condition of the orbit, most often occurring alongside Graves' hyperthyroidism because the same TSH-receptor antibodies act on both the thyroid gland and orbital tissue. It is not simply "what happens to your eyes when your thyroid is high" — the eye disease can appear before hormone levels are corrected, after, or even in people whose thyroid function is normal. What decides the clinical picture is not the hormone level but how much the orbital tissue swells inside a bony space that has no room to give, and whether that crowding reaches the optic nerve at the back.
Section 02 — Interactive
The same swelling,
two different directions.
When the extraocular muscles enlarge inside the orbit, the extra tissue has to go somewhere. In a more fat-compliant orbit, it tends to push the eye forward — proptosis. In a tighter, more fibrotic orbit, the same swelling crowds backward toward the orbital apex, where the optic nerve exits — the pattern most associated with vision-threatening compression, sometimes with only modest forward bulging to show for it. Adjust muscle enlargement and orbital phenotype below to see why the two patterns need very different levels of concern.
This dual-outcome idea — forward displacement versus posterior crowding — is why two patients with what looks like the same degree of muscle swelling on a scan can have very different risk profiles. A proptotic eye is visually obvious and distressing, but a comparatively "good-looking" eye with tight apical crowding can be the one quietly losing optic nerve function, which is exactly why imaging and a formal work-up matter more than how bulging the eye appears from across a room.
Section 03 — The Two-Phase Course
Active, then stable.
Treatment depends
on which one you're in.
TED does not progress in a straight line. Most patients pass through an active, inflammatory phase — pain, redness, swelling, progressive change on exam — that gradually burns out into a stable, fibrotic phase where the tissue changes are fixed but no longer actively worsening. This pattern is often described by Rundle's curve: a rise in severity over the active phase, a plateau, and then a partial spontaneous improvement before disease activity settles. Anti-inflammatory and immunomodulatory treatments are aimed at the active phase; rehabilitative surgery is deliberately deferred until the disease has been stable for months.
To decide which phase a patient is in, ophthalmologists use the Clinical Activity Score (CAS), a bedside checklist of inflammatory signs — spontaneous orbital pain, pain with eye movement, redness of the eyelids and the white of the eye, swelling of the eyelids and conjunctiva, and swelling of the caruncle. A score of 3 or more out of 7 is generally taken as active disease, and it is this score — not the thyroid hormone level on a blood test — that most directly informs whether steroids or other immunomodulatory therapy are likely to help.
| Feature | Active phase | Stable (fibrotic) phase |
|---|---|---|
| Typical duration | Commonly several months up to roughly two years | Indefinite once reached; tissue changes are largely fixed |
| Exam findings | Pain, redness, progressive swelling, worsening measurements visit to visit | Stable measurements over repeated visits; signs of inflammation resolved |
| CAS | Typically 3 or more out of 7 | Typically below 3 |
| Primary treatment lever | Corticosteroids, other immunomodulatory or IGF-1R-targeted therapy, orbital radiotherapy in selected cases | Rehabilitative surgery: decompression, strabismus, eyelid procedures |
| Smoking status | Cessation strongly advised — smoking worsens both severity and treatment response | Cessation still relevant to long-term stability |
Section 04 — What It Looks Like
From eyelid retraction
to a genuine emergency.
Severity spans a wide range. Many patients have mild, mostly cosmetic and irritative disease; a minority progress to something that threatens vision. Recognising where a given presentation sits on that spectrum is the point of the clinical exam.
| Sign | What it is | Severity signal |
|---|---|---|
| Eyelid retraction | Upper lid sits higher than normal, exposing white sclera above the iris | Common, often the earliest visible sign |
| Lid lag on downgaze | Upper lid fails to follow the eye smoothly when looking down | Common, mild-to-moderate disease |
| Proptosis / exophthalmos | Forward protrusion of the eye, measured by exophthalmometry | Variable severity; degree alone does not predict nerve risk |
| Chemosis & conjunctival injection | Swelling and redness of the eye's surface membrane | Marker of active inflammation (part of CAS) |
| Restrictive strabismus / diplopia | Fibrotic, non-elastic muscles (commonly the inferior and medial recti) restrict eye movement, causing double vision | Functionally disabling; usually addressed once stable |
| Exposure keratopathy | Cornea dries and can ulcerate when lids can no longer fully close over a proptotic eye | Sight-threatening if severe |
| Compressive optic neuropathy | Apex crowding presses on the optic nerve, reducing colour vision and acuity | Ophthalmic emergency |
Section 05 — The Evidence
What treatment trials
actually show.
Management has shifted meaningfully with the arrival of targeted medical therapy for active-phase disease. Teprotumumab, a monoclonal antibody against the IGF-1 receptor — a co-signalling partner of the TSH receptor implicated in driving orbital fibroblast activity — was studied against placebo in randomised trials and represented the first therapy purpose-built for TED rather than adapted from general immunosuppression.
Illustrative visualisation of the direction and rough magnitude reported in the pivotal teprotumumab trial literature — see References. Rounded figures, not exact trial statistics, and not a substitute for the original data.
The pivotal randomised trial of teprotumumab, published by Douglas and colleagues in the New England Journal of Medicine, established the proptosis-responder benefit summarised above and led to regulatory approval for active TED in the United States. It is not free of trade-offs: the trial and subsequent post-approval experience documented side effects including elevated blood glucose, muscle spasms, and hearing-related symptoms such as tinnitus or hearing impairment, some of which have persisted after treatment in a subset of patients — which is why candidacy, baseline hearing and glucose status, and informed counselling on the risk profile matter as much as the efficacy numbers.
The European Group on Graves' Orbitopathy (EUGOGO) consensus guidelines, most recently updated in 2021, remain the reference framework most clinicians outside pivotal-trial settings use to classify severity (mild / moderate-to-severe / sight-threatening) and route patients to the appropriate pathway — observation and risk-factor control for mild disease, immunomodulatory therapy for active moderate-to-severe disease, and urgent intervention for sight-threatening disease.
for active disease
EUGOGO guidelines
in fixed order
Section 06 — Risk, Honestly Stated
Medical therapy
and surgery
both carry real trade-offs.
Neither the medical nor the surgical pathway is risk-free, and a guide that only lists one side is not useful for a patient actually weighing the decision with their care team.
| Approach | What it's for | Real trade-offs |
|---|---|---|
| Corticosteroids (oral/IV) | Active-phase inflammation, moderate-to-severe or sight-threatening disease | Weight gain, mood changes, glucose elevation, bone density loss with prolonged use |
| Teprotumumab | Active, moderate-to-severe disease, particularly with troubling proptosis | Hyperglycaemia, muscle spasm, infusion reactions, hearing impairment/tinnitus that can be lasting |
| Orbital radiotherapy | Active disease, sometimes combined with steroids | Modest effect on its own by most series; not appropriate in diabetic retinopathy or in very young patients |
| Orbital decompression surgery | Stable disease with disfiguring proptosis or urgent optic nerve compression | Can worsen or induce new double vision, numbness, sinus-related complications |
| Strabismus surgery | Stable disease with persistent restrictive diplopia | Outcomes less predictable than routine strabismus surgery due to fibrotic muscle behaviour; may need more than one procedure |
| Eyelid surgery | Stable disease with persistent lid retraction or exposure | Under- or over-correction possible; done last so earlier steps aren't undone |
Section 07 — Where the Decision Gets Made
A team decision,
built on a specific work-up.
TED management sits between endocrinology and ophthalmology, and the useful work-up looks the same regardless of which specialist a patient sees first: thyroid function tests and TSH-receptor antibody titre, a CAS assessment, Hertel exophthalmometry to measure proptosis objectively, formal visual field and colour vision testing if apex crowding is suspected, and orbital CT or MRI when surgery or a compressive-neuropathy question is on the table.
A patient with Graves' disease and only mild-looking forward eye protrusion reports new difficulty distinguishing colours and a subtle dimming in one eye. On the appearance of the eyes alone, this would not seem urgent — there is no dramatic bulging. But imaging shows disproportionate crowding of the muscles at the orbital apex relative to how far the eye has moved forward, consistent with a tight, fibrotic orbital phenotype. The colour vision change is the tell: it prompts urgent visual field testing and same-week ophthalmology referral rather than routine follow-up, because compressive optic neuropathy can be present with only modest visible proptosis.
Once the disease is confirmed stable — a low CAS sustained across repeat visits, not just a single good day — surgical rehabilitation, if needed, follows a fixed order: orbital decompression first (to correct proptosis and relieve any apex crowding), then strabismus surgery (to correct the diplopia decompression itself did not fix and may have shifted), then eyelid surgery last (retraction repair or blepharoplasty, once the eye's final position is settled). Each step is sequenced this way because operating out of order risks undoing the step before it.
Section 08 — FAQ
Frequently asked questions
about thyroid eye disease.
Thyroid eye disease (TED), also called Graves' orbitopathy or Graves' ophthalmopathy, is an autoimmune condition in which the immune system attacks tissue inside the eye socket — the fat, connective tissue and muscles that move the eye — causing inflammation, swelling and, over time, tissue enlargement within a bony space that cannot expand to make room. It is most commonly linked to Graves' disease, the autoimmune cause of an overactive thyroid, but the eye disease and the thyroid hormone level do not always move together.
No. An overactive thyroid (hyperthyroidism) is a hormone problem; thyroid eye disease is a separate autoimmune process that happens to share the same underlying trigger — antibodies against the TSH receptor, which is also present on cells in the orbit. TED can appear before, during, or after thyroid hormone levels are corrected, and a minority of cases occur in people whose thyroid function is normal or even underactive.
The Clinical Activity Score (CAS) is a checklist ophthalmologists use to judge whether TED is currently in its active, inflammatory phase — scoring signs such as spontaneous orbital pain, pain on eye movement, redness and swelling of the lids and surface of the eye. A score of 3 or more out of 7 is generally taken to mean the disease is active, which is the main factor in deciding whether anti-inflammatory or immunomodulatory medical treatment is likely to help, as opposed to waiting for the disease to burn out before considering surgery.
TED becomes sight-threatening — a genuine ophthalmic emergency — in two situations: compressive optic neuropathy, where swollen muscles crowd the orbital apex and press on the optic nerve, and severe corneal exposure, where the eyelids can no longer close over a proptotic eye, risking corneal ulceration. Warning signs include a drop in colour vision or visual acuity, and either needs urgent same-week ophthalmology assessment, not a routine follow-up.
Teprotumumab is a monoclonal antibody that blocks the IGF-1 receptor, a co-signalling partner of the TSH receptor implicated in driving orbital tissue expansion in TED. In its pivotal randomised trial, roughly four out of five patients treated with teprotumumab achieved a clinically meaningful reduction in eye protrusion, compared to roughly one in ten on placebo, and it also improved double vision and disease activity scores for many patients. It is given as an infusion course and carries its own side-effect profile, including elevated blood sugar, muscle cramps, and hearing-related symptoms that require monitoring.
Once the disease has been stable and inactive for some months, surgical rehabilitation is generally sequenced as orbital decompression first, then eye-muscle (strabismus) surgery, then eyelid surgery — because each step can change the eye's position and the tension on nearby tissue, which would undo work done out of order. Decompression is done first because moving the eye further back or removing crowding tissue is most likely to require the muscle and eyelid positions to be readjusted afterward, not the reverse.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
Thyroid Eye Disease (Graves' Orbitopathy): Symptoms, Stages & Treatment (2026 Guide)